Search Results - "Hejazi, Nima S."

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial by Gilbert, Peter B, Montefiori, David C, McDermott, Adrian B, Fong, Youyi, Benkeser, David, Deng, Weiping, Zhou, Honghong, Houchens, Christopher R, Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Flach, Britta, Lin, Bob C, O'Connell, Sarah, McDanal, Charlene, Eaton, Amanda, Sarzotti-Kelsoe, Marcella, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, van der Laan, Lars W P, Hejazi, Nima S, Huynh, Chuong, Miller, Jacqueline, El Sahly, Hana M, Baden, Lindsey R, Baron, Mira, De La Cruz, Luis, Gay, Cynthia, Kalams, Spyros, Kelley, Colleen F, Andrasik, Michele P, Kublin, James G, Corey, Lawrence, Neuzil, Kathleen M, Carpp, Lindsay N, Pajon, Rolando, Follmann, Dean, Donis, Ruben O, Koup, Richard A

“…In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed for neutralizing and binding antibodies as correlates of risk for…”
Get full text

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults by Gray, Glenda E, Bekker, Linda-Gail, Laher, Fatima, Malahleha, Mookho, Allen, Mary, Moodie, Zoe, Grunenberg, Nicole, Huang, Yunda, Grove, Doug, Prigmore, Brittany, Kee, Jia J, Benkeser, David, Hural, John, Innes, Craig, Lazarus, Erica, Meintjes, Graeme, Naicker, Nivashnee, Kalonji, Dishiki, Nchabeleng, Maphoshane, Sebe, Modulakgotla, Singh, Nishanta, Kotze, Philip, Kassim, Sheetal, Dubula, Thozama, Naicker, Vimla, Brumskine, William, Ncayiya, Cleon N, Ward, Amy M, Garrett, Nigel, Kistnasami, Girisha, Gaffoor, Zakir, Selepe, Pearl, Makhoba, Philisiwe B, Mathebula, Matsontso P, Mda, Pamela, Adonis, Tania, Mapetla, Katlego S, Modibedi, Bontle, Philip, Tricia, Kobane, Gladys, Bentley, Carter, Ramirez, Shelly, Takuva, Simbarashe, Jones, Megan, Sikhosana, Mpho, Atujuna, Millicent, Andrasik, Michele, Hejazi, Nima S, Puren, Adrian, Wiesner, Lubbe, Phogat, Sanjay, Diaz Granados, Carlos, Koutsoukos, Marguerite, Van Der Meeren, Olivier, Barnett, Susan W, Kanesa-Thasan, Niranjan, Kublin, James G, McElrath, M. Juliana, Gilbert, Peter B, Janes, Holly, Corey, Lawrence

“…In this trial, investigators evaluated the efficacy of the ALVAC–gp120 HIV vaccine in 5404 healthy adults in South Africa. At 24 months, there was no…”
Get full text

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial by Fong, Youyi, Huang, Yunda, Benkeser, David, Carpp, Lindsay N., Áñez, Germán, Woo, Wayne, McGarry, Alice, Dunkle, Lisa M., Cho, Iksung, Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Petropoulos, Christos J., Leith, Andrew, Haugaard, Deanne, Webb, Bill, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, van der Laan, Lars W. P., Hejazi, Nima S., Randhawa, April K., Andrasik, Michele P., Kublin, James G., Hutter, Julia, Keshtkar-Jahromi, Maryam, Beresnev, Tatiana H., Corey, Lawrence, Neuzil, Kathleen M., Follmann, Dean, Ake, Julie A., Gay, Cynthia L., Kotloff, Karen L., Koup, Richard A., Donis, Ruben O., Gilbert, Peter B.

“…In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike binding IgG concentration (spike IgG), anti-RBD binding IgG concentration…”
Get full text

Functional Profiling Identifies Determinants of Arsenic Trioxide Cellular Toxicity by Sobh, Amin, Loguinov, Alex, Yazici, Gulce Naz, Zeidan, Rola S, Tagmount, Abderrahmane, Hejazi, Nima S, Hubbard, Alan E, Zhang, Luoping, Vulpe, Chris D

“…Abstract Arsenic exposure is a worldwide health concern associated with an increased risk of skin, lung, and bladder cancer but arsenic trioxide (AsIII) is…”
Get full text

Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial by Carpp, Lindsay N., Hyrien, Ollivier, Fong, Youyi, Benkeser, David, Roels, Sanne, Stieh, Daniel J., Van Dromme, Ilse, Van Roey, Griet A., Kenny, Avi, Huang, Ying, Carone, Marco, McDermott, Adrian B., Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Amoa-Awua, Obrimpong, Basappa, Manjula, Flach, Britta, Lin, Bob C., Moore, Christopher, Naisan, Mursal, Naqvi, Muhammed, Narpala, Sandeep, O’Connell, Sarah, Mueller, Allen, Serebryannyy, Leo, Castro, Mike, Wang, Jennifer, Petropoulos, Christos J., Luedtke, Alex, Lu, Yiwen, Yu, Chenchen, Juraska, Michal, Hejazi, Nima S., Wolfe, Daniel N., Sadoff, Jerald, Gray, Glenda E., Grinsztejn, Beatriz, Goepfert, Paul A., Bekker, Linda-Gail, Gaur, Aditya H., Veloso, Valdilea G., Randhawa, April K., Andrasik, Michele P., Hendriks, Jenny, Truyers, Carla, Vandebosch, An, Struyf, Frank, Schuitemaker, Hanneke, Douoguih, Macaya, Kublin, James G., Corey, Lawrence, Neuzil, Kathleen M., Follmann, Dean, Koup, Richard A., Donis, Ruben O., Gilbert, Peter B.

“…Assessment of immune correlates of severe COVID-19 has been hampered by the low numbers of severe cases in COVID-19 vaccine efficacy (VE) trials. We assess…”
Get full text

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial by Benkeser, David, Montefiori, David C, McDermott, Adrian B, Fong, Youyi, Janes, Holly E, Deng, Weiping, Zhou, Honghong, Houchens, Christopher R, Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Flach, Britta, Lin, Bob C, O'Connell, Sarah, McDanal, Charlene, Eaton, Amanda, Sarzotti-Kelsoe, Marcella, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, van der Laan, Lars W P, Hejazi, Nima S, Kenny, Avi, Carone, Marco, Williamson, Brian D, Garver, Jennifer, Altonen, Erin, Rudge, Thomas, Huynh, Chuong, Miller, Jacqueline, El Sahly, Hana M, Baden, Lindsey R, Frey, Sharon, Malkin, Elissa, Spector, Stephen A, Andrasik, Michele P, Kublin, James G, Corey, Lawrence, Neuzil, Kathleen M, Carpp, Lindsay N, Pajon, Rolando, Follmann, Dean, Donis, Ruben O, Koup, Richard A, Gilbert, Peter B

“…The best assay or marker to define mRNA-1273 vaccine-induced antibodies as a correlate of protection (CoP) is unclear. In the COVE trial, participants received…”
Get more information

Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial by Hejazi, Nima S., Shen, Xiaoying, Carpp, Lindsay N., Benkeser, David, Follmann, Dean, Janes, Holly E., Baden, Lindsey R., El Sahly, Hana M., Deng, Weiping, Zhou, Honghong, Leav, Brett, Montefiori, David C., Gilbert, Peter B.

“…•Stochastic interventional vaccine efficacy (SVE) analysis for clinical audience.•SVE analysis estimates how vaccine efficacy (VE) would change under…”
Get full text

Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial by Fong, Youyi, Huang, Yunda, Benkeser, David, Carpp, Lindsay N., Áñez, Germán, Woo, Wayne, McGarry, Alice, Dunkle, Lisa M., Cho, Iksung, Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Petropoulos, Christos J., Leith, Andrew, Haugaard, Deanne, Webb, Bill, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, van der Laan, Lars W. P., Hejazi, Nima S., Randhawa, April K., Andrasik, Michele P., Kublin, James G., Hutter, Julia, Keshtkar-Jahromi, Maryam, Beresnev, Tatiana H., Corey, Lawrence, Neuzil, Kathleen M., Follmann, Dean, Ake, Julie A., Gay, Cynthia L., Kotloff, Karen L., Koup, Richard A., Donis, Ruben O., Gilbert, Peter B.

Get full text

Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial by Huang, Ying, Hejazi, Nima S, Blette, Bryan, Carpp, Lindsay N, Benkeser, David, Montefiori, David C, McDermott, Adrian B, Fong, Youyi, Janes, Holly E, Deng, Weiping, Zhou, Honghong, Houchens, Christopher R, Martins, Karen, Jayashankar, Lakshmi, Flach, Britta, Lin, Bob C, O'Connell, Sarah, McDanal, Charlene, Eaton, Amanda, Sarzotti-Kelsoe, Marcella, Lu, Yiwen, Yu, Chenchen, Kenny, Avi, Carone, Marco, Huynh, Chuong, Miller, Jacqueline, El Sahly, Hana M, Baden, Lindsey R, Jackson, Lisa A, Campbell, Thomas B, Clark, Jesse, Andrasik, Michele P, Kublin, James G, Corey, Lawrence, Neuzil, Kathleen M, Pajon, Rolando, Follmann, Dean, Donis, Ruben O, Koup, Richard A, Gilbert, Peter B, On Behalf Of The Immune Assays, Moderna Inc, Coronavirus Vaccine Prevention Network CoVPN/Coronavirus Efficacy Cove, United States Government Usg/CoVPN Biostatistics Teams

“…The COVE trial randomized participants to receive two doses of mRNA-1273 vaccine or placebo on Days 1 and 29 (D1, D29). Anti-SARS-CoV-2 Spike IgG binding…”
Get full text

Exploring high-dimensional biological data with sparse contrastive principal component analysis by Boileau, Philippe, Hejazi, Nima S, Dudoit, Sandrine

“…Abstract Motivation Statistical analyses of high-throughput sequencing data have re-shaped the biological sciences. In spite of myriad advances, recovering…”
Get full text

Causal mediation analysis for stochastic interventions by Díaz, Iván, Hejazi, Nima S.

“…Summary Mediation analysis in causal inference has traditionally focused on binary exposures and deterministic interventions, and a decomposition of the…”
Get full text

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine by Benkeser, David, Fong, Youyi, Janes, Holly E., Kelly, Elizabeth J., Hirsch, Ian, Sproule, Stephanie, Stanley, Ann Marie, Maaske, Jill, Villafana, Tonya, Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Ayala, Victor, Petropoulos, Christos J., Leith, Andrew, Haugaard, Deanne, Webb, Bill, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, van der Laan, Lars W. P., Hejazi, Nima S., Carpp, Lindsay N., Randhawa, April K., Andrasik, Michele P., Kublin, James G., Isaacs, Margaret Brewinski, Makhene, Mamodikoe, Tong, Tina, Robb, Merlin L., Corey, Lawrence, Neuzil, Kathleen M., Follmann, Dean, Hoffman, Corey, Falsey, Ann R., Sobieszczyk, Magdalena, Koup, Richard A., Donis, Ruben O., Gilbert, Peter B.

“…In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the U.S., Chile, and Peru, anti-spike binding IgG concentration (spike IgG) and…”
Get full text

A nonparametric framework for treatment effect modifier discovery in high dimensions by Boileau, Philippe, Leng, Ning, Hejazi, Nima S, van der Laan, Mark, Dudoit, Sandrine

“…Abstract Heterogeneous treatment effects are driven by treatment effect modifiers (TEMs), pretreatment covariates that modify the effect of a treatment on an…”
Get full text

When Can Causal-Analytic Methods Inform Design-Based Research? by Hejazi, Nima S.

Get full text

Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial by Gilbert, Peter B., Fong, Youyi, Hejazi, Nima S., Kenny, Avi, Huang, Ying, Carone, Marco, Benkeser, David, Follmann, Dean

“…•Many statistical approaches have been applied to vaccine efficacy (VE) trials to evaluate CoPs.•Four distinct statistical frameworks for evaluating CoPs in VE…”
Get full text

Causal survival analysis under competing risks using longitudinal modified treatment policies by Díaz, Iván, Hoffman, Katherine L., Hejazi, Nima S.

“…Longitudinal modified treatment policies (LMTP) have been recently developed as a novel method to define and estimate causal parameters that depend on the…”
Get full text

Nonparametric inverse‐probability‐weighted estimators based on the highly adaptive lasso by Ertefaie, Ashkan, Hejazi, Nima S., van der Laan, Mark J.

“…Inverse‐probability‐weighted estimators are the oldest and potentially most commonly used class of procedures for the estimation of causal effects. By…”
Get full text

Efficient nonparametric inference on the effects of stochastic interventions under two‐phase sampling, with applications to vaccine efficacy trials by Hejazi, Nima S., van der Laan, Mark J., Janes, Holly E., Gilbert, Peter B., Benkeser, David C.

“…The advent and subsequent widespread availability of preventive vaccines has altered the course of public health over the past century. Despite this success,…”
Get full text

Doubly-Robust Inference in R using drtmle by Benkeser, David, Hejazi, Nima S

Get full text

Nonparametric causal mediation analysis for stochastic interventional (in)direct effects by Hejazi, Nima S, Rudolph, Kara E, Van Der Laan, Mark J, Díaz, Iván

“…Summary Causal mediation analysis has historically been limited in two important ways: (i) a focus has traditionally been placed on binary exposures and static…”
Get full text